NHLBI Translational Research Implementation Program (TRIP) - Limited Competition - (P50)

Post Date

October 1st 2010

Application Due Date

April 4th 2011

Funding Opportunity Number

RFA-HL-12-003

CFDA Number(s)

93.837
93.838
93.839

Funding Instrument Type(s)

Grant

Funding Activity Categories

Health

Eligibility Categories

State Governments
County Governments
City or Township Governments
Special District Governments
Independent School Districts
Public and State Controlled Institutions of Higher Education
Federally Recognized Native American Tribal Governments
Public Housing Authorities or Indian Housing Authorities
Non-Federally Recognized Native American Tribal Organizations
Non-Profits With 501 (c) (3) Status With The IRS (Except Higher Education Institutions)
Non-Profits Without 501 (c) (3) Status With The IRS (Except Higher Education Institutions)
Private Institutions of Higher Education
For-Profit Organizations (Except Small Businesses)
Small Businesses
Other

Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession.

Funding

• Estimated Total Funding:

  $13635000

• Award Range:

  $None - $1515000

Grant Description

Purpose. The National Heart, Lung, and Blood Institute (NHLBI) solicits Stage 2 Specialized Center grants (P50) for the NHLBI Translational Research Implementation Program (TRIP). The overall objective of the entire two-staged NHLBI TRIP is to accelerate translation of promising new therapeutic interventions derived from fundamental research discoveries for the treatment and prevention of cardiovascular, lung, and blood diseases through the planning and execution of well-designed clinical trials to demonstrate safety and efficacy. Previously awarded Stage 1 planning studies, funded either as RC2 or P20 awards, supported the planning and development of Stage 2 specialized center (P50) applications now being solicited to support the conduct of the safety and efficacy trials recommended for support following peer review. The present request for Stage 2 (P50) applications for the conduct of the clinical trials planned and developed during Stage 1 is limited to successful Stage 1 applicants. Thus, this is a limited competition open only to: (1) recipients of NIH Research and Research Infrastructure Grand Opportunities (RC2) awards submitted in response to the NHLBI Translational Research Implementation Program (TRIP) topic and (2) recipients of the NHLBI Cardiac Translational Research Implementation Program (C-TRIP) (P20) awards. Support during Stage 2 TRIP is expected to provide up to $1,515,000 direct costs per year for up to five years per award. Mechanism of Support. This FOA will utilize the Specialized Center grants (P50) award mechanism. Funds Available and Anticipated Number of Awards. NHLBI expects to commit $13,635,000 per year to support the award of up to 6 five-year-long Stage 2 (P50) TRIP awards.

Contact Information

• Agency

  Department of Health and Human Services

• Office:

  National Institutes of Health

• Agency Contact:

  NIH OER Webmaster
  FBOWebmaster@OD.NIH.GOV
  

• Agency Mailing Address:

  If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster

• Agency Email Address:

  FBOWebmaster@OD.NIH.GOV

• More Information:

  http://grants.nih.gov/grants/guide/rfa-files/RFA-HL-12-003.html